

## CAPLIN POINT LABORATORIES LIMITED

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017

CIN - L24231TN1990PLC019053, Phone Nos.044-28156653, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

## UNAUDITED (CONSOLIDATED) FINANCIAL RESULTS FOR THE THREE MONTHS ENDED 30th June 2019

Prepared in compliance with the Indian Accounting Standards (Ind - AS)

	Particulars	Three Months ended			Financial Year Ended
		30.06.2019	31.03. 2019	30.06.2018	31.03.2019
		(1)	(2)	(3)	(4)
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
INR in lakhs					
	<b>Income:</b>				
I	Revenue from operations	19,255.32	18,733.97	14,645.99	64,869.09
II	Other income	446.76	266.67	160.93	1,902.89
<b>III</b>	<b>Total Income (I+II)</b>	<b>19,702.08</b>	<b>19,000.64</b>	<b>14,806.91</b>	<b>66,771.98</b>
	<b>IV Expenses:</b>				
	a. Cost of materials consumed	2,246.33	2,378.79	2,364.99	9,511.76
	b. Purchase of traded goods	12,114.20	6,873.64	4,041.29	20,373.31
	c. Changes in inventories of finished goods, stock in trade and work in progress (Refer Note 11)	(5,842.40)	(632.47)	2.99	(1,007.04)
	d. Employee benefit expenses	1,558.82	1,241.84	1,152.40	4,710.97
	e. Finance cost	1.00	1.36	1.22	6.00
	f. Depreciation & Amortisation Expenses	738.67	671.94	545.33	2,342.50
	g. Other Expenses	2,440.16	2,396.31	1,781.28	8,146.86
	<b>h. Total Expenses</b>	<b>13,256.78</b>	<b>12,931.41</b>	<b>9,889.50</b>	<b>44,084.36</b>
<b>V</b>	<b>Profit before exceptional items and Tax (III-IV)</b>	<b>6,445.30</b>	<b>6,069.23</b>	<b>4,917.42</b>	<b>22,687.62</b>
VI	Exceptional items	-	-	-	-
<b>VII</b>	<b>Profit Before Tax (V-VI)</b>	<b>6,445.30</b>	<b>6,069.23</b>	<b>4,917.42</b>	<b>22,687.62</b>
<b>VIII</b>	<b>Tax Expenses</b>				
	(1) Current Tax	1,449.66	1,962.84	948.55	5,485.70
	(2) Deferred Tax	-11.32	(879.22)	229.46	(453.62)
	<b>Total Tax Expenses</b>	<b>1,438.35</b>	<b>1,083.62</b>	<b>1,178.01</b>	<b>5,032.08</b>
<b>IX</b>	<b>Net Profit for the Year (VII - VIII)</b>	<b>5,006.95</b>	<b>4,985.61</b>	<b>3,739.41</b>	<b>17,655.54</b>
<b>X</b>	<b>Other Comprehensive Income - Net of Income Tax</b>				
	A. Items that will not be re-classified to profit or loss				
	i) Remeasurements of Defined Benefit Plan	(30.34)	(101.30)	14.05	(84.43)
	B. Items that will be re-classified to profit or loss				
	i) Exchange difference in translating the financial statements of foreign operations	(7.06)	(331.45)	(10.42)	58.86
<b>XI</b>	<b>Total Comprehensive Income For The Year (IX + X)</b>	<b>4,969.55</b>	<b>4,552.87</b>	<b>3,743.04</b>	<b>17,629.97</b>
<b>XII</b>	<b>Profit attributable to:</b>				
	Owners of the Company	5,023.45	4,980.59	3,742.90	17,656.70
	Non- controlling interests	(16.51)	5.02	(3.49)	(1.16)
		<b>5,006.95</b>	<b>4,985.61</b>	<b>3,739.41</b>	<b>17,655.54</b>
<b>XIII</b>	<b>Total Comprehensive Income For The Year attributable to</b>				
	Owners of the Company	4,986.06	4,547.83	3,746.53	17,631.13
	Non- controlling interests	(16.51)	5.02	(3.49)	(1.16)
		<b>4,969.55</b>	<b>4,552.87</b>	<b>3,743.04</b>	<b>17,629.97</b>
XIV	Paid up Equity Share Capital (Face value of share of Rs 2/- each)	1,512.86	1,512.61	1,512.07	1,512.61
XV	Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year				58,186.03
<b>XVI</b>	<b>Earnings Per Share (EPS) (Not annualised) based on face value Rs 2/- per Equity share</b>				
	(a) Basic (in Rupees)	6.64	6.58	4.95	23.35
	(b) Diluted (in Rupees)	6.60	6.55	4.92	23.23

Notes :

- 1) The above results have been prepared in accordance with the Companies (Indian Accounting standards) Rules, 2015 ("Ind As") prescribed under Section 133 of the Companies Act, 2013 and other accounting pronouncement generally accepted in India, to the extent applicable.
- 2) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra ordinary item.
- 3) During the three months period ended 30th June 2019, the Company has allotted 12,500 equity shares of Rs 2/- each under the Employee Stock Option Plan 2015 and the total number of equity shares of the Company stands at 7,56,42,750 as on 30th June 2019.
- 4) Effective April 01,2019 the company adopted Ind AS 116 "Leases" and applied the same to the lease contracts existing on April 01,2019 using the modified retrospective approach. The effect of the adoption is not significant to the profit for the period.
- 5) Revenue from operations is disclosed net of Goods & Service Tax
- 6) The Consolidated financial results of the company have been reviewed and recommended by the Audit Committee of the Board and have been approved by the Board of Directors of the Company at their meeting held on 12th Aug 2019.  
  
The Statutory Auditors of the Company have carried out limited review of the above Consolidated Financial Results pursuant to regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulations,2015.An unqualified opinion has been issued by them thereon.
- 7) The figures for the quarter ended 31st March 2019 are the balancing numbers between the audited figures in respect of the full financial year and the published unaudited year-to-date figures upto the end of the third quarter ended 31st December, 2018, which were subjected to limited review.
- 8) Pursuant to the Business Transfer Agreement executed by the Company on 18th January, 2019, the regulated markets injectable business have been transferred to its wholly owned subsidiary company, Caplin Steriles Limited. The results of this subsidiary has been consolidated in the above results.
- 9) During the quarter ended 30th June, 2019 the Company's wholly owned subsidiary Caplin Point Far East Limited, Hong Kong has invested and acquired a majority share (98%) in Neo Ethicals S.A. Nicaragua. The results of this subsidiary has been consolidated in the above results.
- 10) Changes in Inventories as at 30th June 2019 includes the Closing Inventories (along with Inventories-in-transit) of our subsidiary in Nicaragua which was acquired in the current quarter and the Inventories of our subsidiary in El-Salvador which commenced its business operations during the quarter ended 31st March 2019. Hence this is not comparable with the previous periods
- 11) During the quarter ended 30th June 2019, pursuant to the approval granted by members at the Extra ordinary General Meeting held on 26th February 2019, the company's subsidiary Caplin Steriles Ltd has issued and allotted 1,53,95,568 Series A Compulsorily Convertible Preference Shares of face value of ₹ 10/- at a premium of Rs. 19.23/- each to F-Prime Capital Partners Life Sciences Fund VI LP carrying a coupon rate of 0.001% p.a. having a term of 19 years from the date of allotment.
- 12) Prior year / period figures are regrouped / rearranged wherever necessary.

Place: Chennai  
Date: Aug 12, 2019

Dr Sridhar Ganesan  
Managing Director

**CAPLIN POINT LABORATORIES LIMITED**

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017

CIN - L24231TN1990PLC019053, Phone Nos.044-28156653, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

**UNAUDITED (STANDALONE) FINANCIAL RESULTS FOR THE THREE MONTHS ENDED 30th June 2019**

Prepared in compliance with the Indian Accounting Standards (Ind - AS)

	Particulars	Three Months Ended			Financial Year Ended
		30.06.2019	31.03.2019	30.06.2018	31.03.2019
		(1)	(2)	(3)	(4)
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
INR In Lakhs					
	<b>Income:</b>				
I	Revenue from operations	14,026.64	14,074.32	12,516.28	53,690.57
II	Dividend from subsidiary	1,753.01	-	1,648.24	1,648.24
III	Other income	241.43	331.44	157.25	1,891.89
<b>IV</b>	<b>Total Income (I+II+III)</b>	<b>16,021.08</b>	<b>14,405.76</b>	<b>14,321.77</b>	<b>57,230.70</b>
	<b>Expenses:</b>				
V	a. Cost of materials consumed	2,087.61	2,271.37	2,364.99	9,404.33
	b. Purchase of traded goods	3,856.33	3,807.48	3,203.10	14,549.56
	c. Changes in inventories of finished goods, stock in trade and work in progress	238.67	123.96	2.99	(250.61)
	d. Employee benefit expenses	670.18	758.18	1,145.92	4,201.25
	e. Finance cost	1.20	1.34	1.22	5.98
	f. Depreciation & Amortisation Expenses	435.80	415.87	545.23	2,084.32
	g. Other Expenses	1,327.89	1,494.47	1,744.06	6,970.49
	<b>h. Total Expenses</b>	<b>8,617.67</b>	<b>8,872.67</b>	<b>9,007.51</b>	<b>36,965.32</b>
<b>VI</b>	<b>Profit before exceptional items and Tax (IV-V)</b>	<b>7,403.41</b>	<b>5,533.09</b>	<b>5,314.26</b>	<b>20,265.38</b>
VII	Exceptional items	-	-	-	-
<b>VIII</b>	<b>Profit Before Tax (VI-VII)</b>	<b>7,403.41</b>	<b>5,533.09</b>	<b>5,314.26</b>	<b>20,265.38</b>
IX	<b>Tax Expenses</b>				
	(1) Current Tax	1,319.73	1,888.12	948.55	5,410.63
	(2) Deferred Tax	73.12	(387.50)	229.46	38.10
	<b>Total Tax Expenses</b>	<b>1,392.85</b>	<b>1,500.63</b>	<b>1,178.01</b>	<b>5,448.73</b>
<b>X</b>	<b>Net Profit for the Year (VIII-IX)</b>	<b>6,010.56</b>	<b>4,032.46</b>	<b>4,136.25</b>	<b>14,816.65</b>
XI	Other Comprehensive Income/ (Loss) - Net of Income Tax				
	A. Items that will not be re-classified to profit or loss				
	i) Remeasurements of Defined Benefit Plan	(12.63)	(88.80)	14.05	(71.93)
<b>XII</b>	<b>Total Comprehensive Income For The Year (X+XI)</b>	<b>5,997.93</b>	<b>3,943.67</b>	<b>4,150.30</b>	<b>14,744.72</b>
XIII	Paid up Equity Share Capital (Face value of shares of Rs 2/- each)	1,512.86	1,512.61	1,512.07	1,512.61
XIV	Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year				41,691.88
<b>XV</b>	<b>Earnings Per Share (EPS) (Not annualised) based on face value Rs 2/- per Equity share</b>				
	<b>(a) Basic (in Rupees)</b>	<b>7.95</b>	<b>5.34</b>	<b>5.47</b>	<b>19.60</b>
	<b>(b) Diluted (in Rupees)</b>	<b>7.90</b>	<b>5.31</b>	<b>5.45</b>	<b>19.50</b>

**Notes :**

- The above results have been prepared in accordance with the Companies (Indian Accounting standards) Rules, 2015 ("Ind As") prescribed under Section 133 of the Companies Act, 2013 and other accounting pronouncement generally accepted in India, to the extent applicable.
- 1) The standalone financial results of the company have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors of the Company at their meeting held on 12th Aug 2019.
- The Statutory Auditors of the Company have carried out limited review of the above Standalone Financial Results pursuant to regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulations, 2015. An unqualified opinion has been issued by them thereon.
- 2) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra ordinary item.
  - 3) Effective April 01, 2019 the company adopted Ind AS 116 "Leases" and applied the same to the lease contracts existing on April 01, 2019 using the modified retrospective approach. The effect of the adoption is not significant to the profit for the period.
  - 4) Revenue from operations is disclosed net of Goods and Service Tax
  - 5) During the three months period ended 30th June 2019, the Company has allotted 12,500 equity shares of Rs 2/- each under the Employee Stock Option Plan 2015 and the total number of equity shares of the Company stands at 7,56,42,750 as on 30th June 2019.
  - 6) Pursuant to the Business Transfer Agreement executed by the Company on 18th January, 2019, the regulated markets injectable business (including USFDA approved injectable plant and DSIR recognized R&D Units CP4 & CP5) have been transferred to its wholly owned subsidiary company, Caplin Steriles Limited. Hence the results of the current quarter ended 30th June, 2019 are not comparable with the corresponding previous periods / previous quarter
  - 7) The figures for the quarter ended 31st March 2019 are the balancing numbers between the audited figures in respect of the full financial year and the published unaudited year-to-date figures upto the end of the third quarter ended 31st December, 2018, which were subjected to limited review.
  - 8) Prior year / period figures are regrouped / rearranged wherever necessary.

**Place: Chennai**  
**Date: August 12, 2019**

**Dr Sridhar Ganesan**  
Managing Director